On the public citation graph

Determinants of R&D Project Abandonment: Evidence from the Pharmaceutical Industry

https://doi.org/10.2139/ssrn.4613631
0 signed · 88 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2020.1166openalex-extracted
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
inferredcites →https://doi.org/10.1002/(sici)1097-0266(199603)17:3<197::aid-smj804>3.0.co;2-uopenalex-extracted
CUSTOMER POWER, STRATEGIC INVESTMENT, AND THE FAILURE OF LEADING FIRMS
inferredcites →https://doi.org/10.1002/0470114754openalex-extracted
An Introduction to Categorical Data Analysis
inferredcites →https://doi.org/10.1002/hec.1454openalex-extracted
Spending on new drug development1
inferredcites →https://doi.org/10.1002/mde.1343openalex-extracted
Mergers and acquisitions in the pharmaceutical and biotech industries
inferredcites →https://doi.org/10.1002/smj.4250171011openalex-extracted
Strategy making as iterated processes of resource allocation
inferredcites →https://doi.org/10.1002/smj.540openalex-extracted
Experience and scale and scope economies: trade‐offs and performance in development
inferredcites →https://doi.org/10.1007/978-1-4614-5251-5openalex-extracted
Organizational Learning: Creating, Retaining and Transferring Knowledge
inferredcites →https://doi.org/10.1007/978-3-662-05693-6openalex-extracted
Analyse von Tabellen und kategorialen Daten
inferredcites →https://doi.org/10.1007/s10645-008-9089-yopenalex-extracted
Financial Constraints and Other Obstacles: are they a Threat to Innovation Activity?
inferredcites →https://doi.org/10.1007/s43546-021-00163-5openalex-extracted
Innovation crisis in the pharmaceutical industry? A survey
inferredcites →https://doi.org/10.1016/0048-7333(82)90016-6openalex-extracted
Technological paradigms and technological trajectories
inferredcites →https://doi.org/10.1016/j.drudis.2012.10.010openalex-extracted
Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift
inferredcites →https://doi.org/10.1016/j.econlet.2017.06.014openalex-extracted
A Simple Model of Mergers and Innovation
inferredcites →https://doi.org/10.1016/j.econlet.2018.02.021openalex-extracted
Duplicative research, mergers and innovation
inferredcites →https://doi.org/10.1016/j.ijindorg.2008.04.003openalex-extracted
Mergers and innovation in big pharma
inferredcites →https://doi.org/10.1016/j.ijindorg.2010.06.003openalex-extracted
The impact of FDI through mergers and acquisitions on innovation in target firms
inferredcites →https://doi.org/10.1016/j.ijindorg.2018.03.001openalex-extracted
Horizontal mergers and product innovation
inferredcites →https://doi.org/10.1016/j.ijindorg.2018.10.003openalex-extracted
How mergers affect innovation: Theory and evidence
inferredcites →https://doi.org/10.1016/j.jhealeco.2004.09.006openalex-extracted
Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances
inferredcites →https://doi.org/10.1016/j.jhealeco.2008.01.002openalex-extracted
Market incentives and pharmaceutical innovation
inferredcites →https://doi.org/10.1016/j.respol.2011.09.008openalex-extracted
What hampers innovation? Revealed barriers versus deterring barriers
inferredcites →https://doi.org/10.1016/j.respol.2015.10.006openalex-extracted
Learning-by-failing. An empirical exercise on CIS data
inferredcites →https://doi.org/10.1016/j.techfore.2017.05.029openalex-extracted
Financial Constraints and the Failure of Innovation Projects
inferredcites →https://doi.org/10.1016/s0167-6296(01)00108-4openalex-extracted
Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research
inferredcites →https://doi.org/10.1016/s1138-5758(10)70024-4openalex-extracted
Determinants of Abandoning Innovative Activities: Evidence from Spanish Firms
inferredcites →https://doi.org/10.1016/s1574-0064(00)80038-4openalex-extracted
Chapter 25 The pharmaceutical industry
inferredcites →https://doi.org/10.1017/cbo9780511615139openalex-extracted
Organizational Learning from Performance Feedback
inferredcites →https://doi.org/10.1021/jm402001wopenalex-extracted
“New Drug” Designations for New Therapeutic Entities: New Active Substance, New Chemical Entity, New Biological Entity, New Molecular Entity
inferredcites →https://doi.org/10.1038/clpt.2009.295openalex-extracted
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
inferredcites →https://doi.org/10.1038/clpt.2010.286openalex-extracted
Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009
inferredcites →https://doi.org/10.1038/clpt.2014.145openalex-extracted
Accelerated Access to Innovative Medicines for Patients in Need
inferredcites →https://doi.org/10.1038/nbt.2786openalex-extracted
Clinical development success rates for investigational drugs
inferredcites →https://doi.org/10.1038/nrd1470openalex-extracted
Can the pharmaceutical industry reduce attrition rates?
inferredcites →https://doi.org/10.1038/nrd2961openalex-extracted
Lessons from 60 years of pharmaceutical innovation
inferredcites →https://doi.org/10.1038/nrd3078openalex-extracted
How to improve R&D productivity: the pharmaceutical industry's grand challenge
inferredcites →https://doi.org/10.1038/nrd3405openalex-extracted
The productivity crisis in pharmaceutical R&D
inferredcites →https://doi.org/10.1038/nrd3514openalex-extracted
The impact of mergers on pharmaceutical R&D
inferredcites →https://doi.org/10.1038/nrd3681openalex-extracted
Diagnosing the decline in pharmaceutical R&D efficiency
inferredcites →https://doi.org/10.1038/nrd4090openalex-extracted
Phase II and Phase III attrition rates 2011–2012
inferredcites →https://doi.org/10.1038/nrd884openalex-extracted
Value of novelty?
inferredcites →https://doi.org/10.1067/mcp.2001.115446openalex-extracted
Risks in new drug development: Approval success rates for investigational drugs
inferredcites →https://doi.org/10.1080/08956308.1991.11670715openalex-extracted
When Choosing R&D Projects, Go with Long Shots
inferredcites →https://doi.org/10.1080/08956308.1996.11671064openalex-extracted
Applying ‘Options Thinking’ To R&D Valuation
inferredcites →https://doi.org/10.1080/095373202200002104openalex-extracted
Innovation in Pharmaceuticals: Perspectives on the Co-ordination, Combination and Creation of Capabilities
inferredcites →https://doi.org/10.1080/10438590701538432openalex-extracted
IMPACT OF FINANCIAL CONSTRAINTS ON INNOVATION: WHAT CAN BE LEARNED FROM A DIRECT MEASURE?
inferredcites →https://doi.org/10.1080/19416520802211446openalex-extracted
1 Moving Beyond Schumpeter: Management Research on the Determinants of Technological Innovation
inferredcites →https://doi.org/10.1086/712506openalex-extracted
Killer Acquisitions
inferredcites →https://doi.org/10.1093/acprof:oso/9780199269426.003.0009openalex-extracted
Technologies, Products and Organization in the Innovating Firm: What Adam Smith Tells Us and Joseph Schumpeter Doesn't
inferredcites →https://doi.org/10.1093/biostatistics/kxx069openalex-extracted
Estimation of clinical trial success rates and related parameters
inferredcites →https://doi.org/10.1093/icc/3.3.537-aopenalex-extracted
The Dynamic Capabilities of Firms: an Introduction
inferredcites →https://doi.org/10.1093/icc/dts027openalex-extracted
Where there is a will, there is a way? Assessing the impact of obstacles to innovation
inferredcites →https://doi.org/10.1093/joclec/nhy010openalex-extracted
HORIZONTAL MERGERS AND INNOVATION‡
inferredcites →https://doi.org/10.1093/oep/gpm044openalex-extracted
Financial constraints to innovation in the UK: evidence from CIS2 and CIS3
inferredcites →https://doi.org/10.1093/oxfordhb/9780199742998.001.0001openalex-extracted
The Oxford Handbook of the Economics of the Biopharmaceutical Industry
inferredcites →https://doi.org/10.1109/17.62322openalex-extracted
The causes of project failure
inferredcites →https://doi.org/10.1109/tem.2018.2798922openalex-extracted
Pulling the Plug? Investigating Firm-Level Drivers of Innovation Project Termination
inferredcites →https://doi.org/10.1111/1756-2171.12133openalex-extracted
The road not taken: competition and the R&D portfolio
inferredcites →https://doi.org/10.1111/j.0737-6782.2004.00075.xopenalex-extracted
Managing a Portfolio of Interdependent New Product Candidates in the Pharmaceutical Industry
inferredcites →https://doi.org/10.1142/s1363919603000830openalex-extracted
Success and Failure of Innovation: A Literature Review
inferredcites →https://doi.org/10.1146/annurev.so.14.080188.001535openalex-extracted
Organizational Learning
inferredcites →https://doi.org/10.1177/0003603x18822576openalex-extracted
Mergers and Innovation
inferredcites →https://doi.org/10.1186/s12967-020-02313-zopenalex-extracted
The endless frontier? The recent increase of R&D productivity in pharmaceuticals
inferredcites →https://doi.org/10.1186/s41231-019-0050-7openalex-extracted
Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles
inferredcites →https://doi.org/10.1200/jco.2006.09.0803openalex-extracted
Economics of New Oncology Drug Development
inferredcites →https://doi.org/10.1257/0895330027247openalex-extracted
Evolutionary Theorizing in Economics
inferredcites →https://doi.org/10.1257/jel.20161327openalex-extracted
Economics of the Pharmaceutical Industry
inferredcites →https://doi.org/10.1287/mnsc.1090.1055openalex-extracted
A Breath of Fresh Air? Firm Type, Scale, Scope, and Selection Effects in Drug Development
inferredcites →https://doi.org/10.1287/mnsc.48.3.343.7727openalex-extracted
Structuring the New Product Development Pipeline
inferredcites →https://doi.org/10.1287/orsc.1.2.195openalex-extracted
Structural Evolution Through Idiosyncratic Jobs: The Potential for Unplanned Learning
inferredcites →https://doi.org/10.1377/hlthaff.25.2.452openalex-extracted
The Quantity And Quality Of Worldwide New Drug Introductions, 1982–2003
inferredcites →https://doi.org/10.1586/ecp.11.13openalex-extracted
The use of multi-target drugs in the treatment of neurodegenerative diseases
inferredcites →https://doi.org/10.2139/ssrn.3049338openalex-extracted
Horizontal Mergers, Innovation and the Competitive Process
inferredcites →https://doi.org/10.2139/ssrn.607941openalex-extracted
Pharmaceutical Development Phases: A Duration Analysis
inferredcites →https://doi.org/10.2165/00019053-200422002-00002openalex-extracted
The Economics of Follow-on Drug Research and Development
inferredcites →https://doi.org/10.2307/1884852openalex-extracted
A BEHAVIORAL MODEL OF RATIONAL CHOICE
inferredcites →https://doi.org/10.2307/1913056openalex-extracted
A Behavioral Theory of the Firm
inferredcites →https://doi.org/10.2307/2392832openalex-extracted
Technological Discontinuities and Organizational Environments
inferredcites →https://doi.org/10.2307/2393549openalex-extracted
Architectural Innovation: The Reconfiguration of Existing Product Technologies and the Failure of Established Firms
inferredcites →https://doi.org/10.2307/2393591openalex-extracted
Performance, Aspirations, and Risky Organizational Change
inferredcites →https://doi.org/10.2307/2555791openalex-extracted
Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery
inferredcites →https://doi.org/10.2307/3094808openalex-extracted
Strategy as Vector and the Inertia of Coevolutionary Lock-in
inferredcites →https://doi.org/10.2307/4131455openalex-extracted
Selection-Based Learning: The Coevolution of Internal and External Selection in High-Velocity Environments
inferredcites →https://doi.org/10.4159/9780674038288openalex-extracted
Organizational Ecology
inferredcites →https://doi.org/10.5465/19416520802211446openalex-extracted
inferredcites →https://doi.org/10.5465/ambpp.1996.4980460openalex-extracted
PERFORMANCE, ASPIRATIONS AND RISKY ORGANIZATIONAL CHANGE.
inferredcites →https://doi.org/10.5465/amd.2018.0024openalex-extracted
Optionality and Selectiveness in Innovation
inferredcites →https://doi.org/10.1007/s11151-019-09679-5openalex-snapshot
Competition, Mergers, and R&D Diversity
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.